CDDO Methyl Ester

CDDO Methyl Ester is an agonist for the KEAP1-Nrf2 pathway. This product is provided as 5 mg of dry powder.

Catalog #: 92-1147 Size: 5 mg


Biological Information
Background Information:
CDDO Methyl Ester (bardoxolone methyl) is a semi-synthetic triterpenoid developed from the oleanolic acid scaffold that induces apoptosis and differentiation in tumor cells. Agonist of the KEAP1-Nrf2 pathway, thus inducing expression of antioxidant proteins and protection against oxidative damage from injury and inflammation. Also an antagonist of the NF-kB pro-inflammatory transcription factor and PPARG. Underwent clinical trials for type 2 diabetes treatment, due to its potent antidiabetic activity, but was confirmed to enhance cardiac disease during a phase 2 trial in October 2012. Provided as 5 mg of dry powder.
Target Name:
Bardoxolone Methyl
Product Type:
Control Ligands & Inhibitors
Drug Discovery & Development
Storage Conditions:
Store at 2-8°C. Please avoid multiple freeze/thaw cycles.
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Additional Information


92-1147 Datasheet

View Document